deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04732494

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (AdvanTIG-203)

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 Tumor Area Positivity (TAP) ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Sponsor: BeiGene

Conditions Esophageal Squamous Cell Carcinoma
Interventions Ociperlimab Placebo Tislelizumab
Updated 13 times since 2021 Last updated: Dec 23, 2024 Started: Mar 31, 2021 Primary completion: Feb 1, 2023 Completion: Dec 26, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Esophageal Squamous Cell Carcinoma and is currently completed. BeiGene leads this study, which shows 13 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~May 2024 · 7 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 8 earlier versions

  1. Oct 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2022 — Oct 2023 [monthly]

    Recruiting PHASE2

  3. Dec 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  4. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  5. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  6. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  7. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  8. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Bangkok, Thailand , Barcelona, Spain , Beijing, China , Changzhi, China , Changzhou, China , Chiang Mai, Thailand , Chiayi City, Taiwan , Deyang, China , Fujian, China and 49 more locations